Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. Expert Rev Vaccines 2013 Jun;12(6):617-29
Date
06/12/2013Pubmed ID
23750792DOI
10.1586/erv.13.40Scopus ID
2-s2.0-84879066944 (requires institutional sign-in at Scopus site) 14 CitationsAbstract
Concurrent with the US FDA's approval of the first therapeutic cancer vaccine, and supported by mounting clinical evidence indicating that targeting carcinoembryonic antigen (CEA) can safely overcome pre-existing tolerance, a multitude of novel CEA cancer vaccines are now in various stages of development. Since cancer-driven immune suppression often limits the efficacy of vaccines, numerous strategies are being examined in both preclinical and clinical settings to overcome immunosuppressive elements, including the combined use of vaccines with certain chemotherapies, immune checkpoint inhibitors, small-molecule targeted therapies and radiation. This review discusses the current state and future direction of therapeutic cancer vaccines targeting CEA, based on advances achieved over the last 5 years.
Author List
Gameiro SR, Jammeh ML, Hodge JWAuthor
Momodou L. Jammeh MD Assistant Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Cancer VaccinesCarcinoembryonic Antigen
Clinical Trials as Topic
Drug Discovery
Humans
United States
